Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Multiple Myeloma 8Leukemia 6Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Burkitt Lymphoma 3Recurrence 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Plasma Cell 2Lymphoma 2Leukemia, T-Cell 2Waldenstrom Macroglobulinemia 1Vomiting 1Uterine Cervical Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Fatigue 1Congenital Abnormalities 1Breast Neoplasms 1Breast Carcinoma In Situ 1Brain Neoplasms 1

Interventions

dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Taxes 1Ranitidine 1Paclitaxel 1Famotidine 1Diphenhydramine 1Dexamethasone 1Cimetidine 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Breast Carcinoma In Situ × Dexamethasone × Clear all
NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Ohio State University Comprehensive Cancer Center

Phase 2/3 Completed
130 enrolled 8 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡